First-in-human trial of RX 3117 in patients with solid tumours.
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2016
At a glance
- Drugs Fluorocyclopentenylcytosine (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- 06 Jun 2016 Results published in Rexahn Pharmaceuticals media release.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 06 Aug 2012 Primary endpoint 'Drug-bioavailability' has been met.